|Bid||1.5300 x 3200|
|Ask||1.5400 x 3200|
|Day's Range||1.5000 - 1.6500|
|52 Week Range||0.9900 - 5.1900|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.40|
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.